Myostatin inhibitor

ACE-031

Also known as ACVR2B

A myostatin trap studied for major muscle-mass gains.

Early / anecdotal

Overview

ACE-031, also known by its receptor designation ACVR2B, is a myostatin inhibitor - but it works differently from Follistatin 344. Rather than blocking myostatin directly, ACE-031 acts as a decoy receptor. It is a soluble form of the ACVR2B receptor, which normally receives myostatin and related muscle-limiting signals (called activins and GDF-11). By flooding the system with this decoy receptor, ACE-031 soaks up those inhibitory signals before they can reach actual muscle tissue, effectively removing the brake on muscle mass. Its goal is muscle building. It is taken by subcutaneous injection on an infrequent schedule, in pulsed cycles. Both dose and timing are set per protocol at consult. The safety context here is critical and should not be minimized. ACE-031 was evaluated in human clinical trials, and those trials were paused due to bleeding and vascular side effects observed in participants. This makes it a compound that is used very cautiously, with close clinical monitoring, and only in appropriate clinical contexts. The evidence is classified as anecdotal, reflecting both the limited completed data and the trial pause. It is investigational with trials halted. Anyone with a history of cancer is excluded. There are no listed stacking partners. Given the vascular safety history, thorough clinical evaluation before any use is essential. Exact dosing is set with a licensed provider in the PepDepo network at consult.

At a glance

Route

SC injection

Dose

Per protocol

Frequency

Infrequent

Timing

Per protocol

Cycle

Pulsed

Safety

Trials paused over bleeding/vascular side effects; used cautiously.

Regulatory: Investigational (trials halted).

Not appropriate if: cancer-history.

Questions

How is ACE-031 different from other myostatin inhibitors like Follistatin 344?⌄

Follistatin 344 binds to myostatin directly. ACE-031 acts as a decoy receptor - it is a soluble version of the ACVR2B receptor that soaks up myostatin and related inhibitory signals before they reach muscle tissue.

What are the safety concerns with ACE-031?⌄

Clinical trials were paused due to bleeding and vascular side effects observed in participants. This is a significant safety history that drives the 'used cautiously' classification and close monitoring during any use.

How is it taken?⌄

Subcutaneous injection on an infrequent schedule, in pulsed cycles. Dose and timing are both set per protocol at consult. This is not a daily compound.

Who should not use ACE-031?⌄

Anyone with a history of cancer is excluded. Additionally, the vascular side effects seen in trials mean anyone with cardiovascular concerns requires particularly thorough clinical evaluation.

What is its current regulatory status?⌄

It is investigational with trials halted. It is not FDA-approved. Use is limited, cautious, and under close clinical supervision.

What goal does ACE-031 target?⌄

Muscle building is its sole listed goal. It is specifically for patients where maximizing muscle mass is the primary objective.

What does 'decoy receptor' mean in practice?⌄

ACE-031 is a soluble copy of a receptor that myostatin would normally dock onto inside muscle tissue. When there is an excess of that decoy floating in circulation, myostatin binds to it instead of reaching muscle, blunting the growth-limiting signal.

Want a personalized protocol?

Exact dosing is set with a licensed provider in the PepDepo network. This page is education, not a prescription.

Book a consult

Education only, not medical advice. Peptides discussed are for informational purposes and many are not FDA-approved. Eligibility, prescribing, compounding, and dispensing are handled by appropriately licensed entities. Exact protocols and dosing are set with a licensed provider in the PepDepo network at consult. Content is pending clinical review.